Estetrol Approvals Mark 'Turning Point' For Mithra
Also Plans Further Launches Of Myring Generic Rival To NuvaRing
Recent Canadian, European and US endorsements of Mithra’s estetrol-based Estelle novel oral contraceptive mark a “turning point” for the Belgian firm, which has also seen success with its Myring generic rival to NuvaRing for which it expects to see further launches this year.
You may also be interested in...
Mithra’s combined oral contraceptive Estelle includes estetrol, the first compound in the contraceptive area to be designated a new active substance in Europe in over 80 years.
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.